PR98498

EAST RUTHERFORD, N.J., Oct. 27, 2022 /PRNewswire=KYODO JBN/ --

Cambrex today announced it is investing in a new, 21,000-square-foot research

and development facility in Minneapolis, Minnesota, expanding its capacity for

small molecule development and manufacturing. Strategically located near the

Minneapolis–St. Paul Airport, the new facility will specialize in analytical

and chemical development for pharmaceutical drug candidates and will operate as

an extension of Cambrex's flagship facility in Charles City, Iowa. Cambrex is

expected to add approximately 40 new jobs over the next 2-3 years at the new

site in Minneapolis.

Cambrex will simultaneously launch a multi-phase, 9,000-square-foot expansion

and 21,000-square-foot renovation project in Charles City, Iowa. The expansion

will add a new quality control laboratory and administrative office space,

which will bring 40 new jobs at the site. The expansive renovations will

enhance and modernize the existing quality control and research and development

facilities. The Iowa Economic Development Authority (IEDA) board awarded the

company tax benefits and 300,000 USD in direct financial assistance to support

the expansion through the High Quality Jobs (HQJ) program.

"Our new facility in Minneapolis will double our analytical and chemical

development footprint in the Midwest, providing clients with easy access to

state-of-the-art capabilities and top scientific experts," said Thomas Loewald,

CEO of Cambrex. "We continue to invest in our U.S.-based footprint to support

the demand for high-quality API development and manufacturing."

This investment follows an earlier 50 million USD expansion in Charles City

that was completed in the first quarter of 2022, establishing Cambrex as the

largest, most advanced active pharmaceutical ingredient (API) manufacturing

site in the United States. The facility is located on a 45-acre property and

produces a wide range of APIs and pharmaceutical intermediates, including

highly potent molecules and controlled substances.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization

(CDMO) that provides drug substance, drug product, and analytical services

across the entire drug lifecycle. With over 40 years of experience and a

growing team of over 2,300 experts servicing global clients from North America

and Europe, Cambrex is a trusted partner in branded and generic markets for API

and finished dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and

capabilities, including continuous flow, controlled substances, solid-state

science, material characterization, stability storage, and highly potent APIs.

In addition, Cambrex can support conventional dosage forms, including oral

solids, semi-solids, and liquids, and has the expertise to manufacture

specialty dosage forms such as modified-release, fixed-dose combination,

pediatric, bi-layer tablets, stick packs, topicals, controlled substances,

sterile, and non-sterile ointments.

Logo: https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg

Source: Cambrex